WuXi PharmaTech (NYSE: WX) Appoints Dr. Peng Wang as VP of Discove...( SHANGHAI China May 26 /Xinhua-- W...)

SHANGHAI, China, May 26 /Xinhua-PRNewswire/ -- WuXi PharmaTech (NYSE: WX), a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, today proudly announced that it has appointed Dr. Peng Wang as Vice President of Discovery Biology.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )

Prior to joining WuXi PharmaTech, Dr. Wang was a research fellow at Schering-Plough Research Institute where he worked for 18 years with increasing responsibilities. He has extensive experience in discovery biology, including target validation research, assay development, screening, in vitro and in vivo biological and pharmacological studies, and mechanism of action and biomarker research. As a discovery team co-chair and biology group leader at Schering-Plough, Dr. Wang made significant contributions to the nomination of several development candidates, four of which are at various phases of clinical trial.

In his new role as Vice President of Discovery Biology, Dr. Wang will oversee the company's growing portfolio of discovery biology service offerings. Dr. Wang will report directly to Dr. Ge Li, Chairman and Chief Executive Officer of WuXi PharmaTech.

"I am very delighted to welcome Dr. Wang on board at this exciting time. Dr. Wang's depth of experience will undoubtedly help the company to accelerate the development of our discovery biology services, and strengthen our medicinal chemistry and biologics discovery capabilities," commented Dr. Ge Li, Chairman and Chief Executive Officer of WuXi PharmaTech.

Dr. Wang received his Ph.D. in Biochemistry from the University of Tokyo, Japan, and has published numerous original biological research articles in the leading and peer-reviewed scientific journals.

About WuXi PharmaTech

WuXi PharmaTech is a
'/>"/>